Profile data is unavailable for this security.
About the company
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
- Revenue in USD (TTM)59.40m
- Net income in USD-8.66m
- Incorporated2014
- Employees41.00
- LocationJourney Medical Corp9237 E Via De Ventura Blvd.Suite 105, Suite 105SCOTTSDALE 85258United StatesUSA
- Phone+1 (480) 434-6670
- Fax+1 (302) 531-3150
- Websitehttps://journeymedicalcorp.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Whitehawk Therapeutics Inc | 14.38m | -15.62m | 134.32m | 22.00 | 20.98 | 0.8546 | -- | 9.34 | 0.1358 | 0.1358 | 0.2802 | 3.33 | 0.1138 | 0.5669 | 4.40 | 359,600.00 | -12.36 | -52.97 | -13.76 | -60.63 | 89.22 | -- | -108.58 | -372.67 | 16.76 | -- | 0.00 | -- | 6.69 | -- | 3.15 | -- | 47.49 | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 152.00m | 1.00 | -- | 0.8486 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Karyopharm Therapeutics Inc | 146.07m | -196.04m | 157.11m | 228.00 | -- | -- | -- | 1.08 | -16.60 | -16.60 | 13.36 | -16.00 | 1.07 | 1.36 | 5.13 | 640,644.80 | -143.71 | -55.11 | -442.98 | -78.19 | 95.93 | 96.83 | -134.21 | -87.65 | 1.08 | -2.11 | 47.44 | -- | 0.5715 | 6.21 | -156.52 | -- | -- | -- |
| Sanara Medtech Inc | 101.90m | -6.24m | 168.97m | 141.00 | -- | 27.47 | -- | 1.66 | -0.7292 | -4.34 | 11.86 | 0.6885 | 1.28 | 2.47 | 8.78 | 722,724.30 | -8.03 | -15.12 | -10.00 | -18.64 | 92.25 | 88.92 | -6.29 | -14.70 | 1.60 | 0.3039 | 0.8801 | -- | 33.36 | 49.09 | -124.59 | -- | -33.05 | -- |
| BGM Group Ltd | 26.85m | -2.72m | 178.70m | 323.00 | -- | 0.5937 | -- | 6.66 | -0.2816 | -0.2816 | 1.38 | 1.85 | 0.2087 | 3.21 | 8.60 | 83,116.91 | -2.08 | -0.0792 | -2.36 | -0.1065 | 19.41 | 10.38 | -9.95 | -0.0921 | 1.45 | -0.3408 | 0.0087 | 2,560.18 | -45.99 | -11.45 | 81.46 | -- | 16.40 | -- |
| Tonix Pharmaceuticals Holding Corp | 10.30m | -99.22m | 193.70m | 81.00 | -- | 0.666 | -- | 18.81 | -20.11 | -20.11 | 1.69 | 22.73 | 0.0593 | 0.9665 | 2.75 | 127,148.10 | -57.12 | -61.84 | -63.76 | -68.67 | 34.31 | -- | -963.38 | -2,797.35 | 9.62 | -- | 0.00 | -- | 29.94 | -- | -11.47 | -- | 47.82 | -- |
| Coherus Oncology Inc | 83.57m | -187.47m | 194.60m | 161.00 | -- | 2.13 | -- | 2.88 | -1.62 | 1.33 | 0.721 | 0.7551 | 0.1636 | 1.76 | 0.9453 | 366,526.30 | -36.70 | -21.44 | -106.02 | -31.54 | 47.79 | 71.26 | -224.34 | -42.66 | 1.23 | -15.12 | 0.3656 | -- | 3.78 | -5.60 | 111.98 | -20.51 | -- | -- |
| Journey Medical Corp | 59.40m | -8.66m | 210.69m | 41.00 | -- | 7.87 | -- | 3.55 | -0.3645 | -0.3645 | 2.58 | 0.982 | 0.796 | 1.79 | 4.15 | 1,448,756.00 | -11.61 | -22.37 | -22.74 | -50.55 | 64.40 | 59.45 | -14.58 | -27.43 | 1.12 | -3.30 | 0.4928 | -- | -29.11 | 9.96 | -280.79 | -- | 44.27 | -- |
| Mediwound Ltd | 20.93m | -20.60m | 221.66m | 111.00 | -- | 4.41 | -- | 10.59 | -1.90 | -1.90 | 1.93 | 3.91 | 0.2475 | 4.59 | 3.69 | 188,576.60 | -24.36 | -35.38 | -35.12 | -48.39 | 18.53 | 32.18 | -98.43 | -71.55 | 2.48 | -- | 0.1416 | -- | 8.22 | -8.65 | -350.03 | -- | 51.27 | -- |
| Opus Genetics Inc | 14.63m | -68.20m | 251.03m | 18.00 | -- | 39.37 | -- | 17.16 | -1.76 | -1.76 | 0.2952 | 0.0925 | 0.3825 | -- | 3.85 | 812,944.40 | -178.28 | -76.30 | -330.00 | -86.90 | -- | -- | -466.09 | -185.79 | -- | -- | 0.1518 | -- | -42.30 | -- | -476.13 | -- | -- | -- |
| Lifecore Biomedical Inc | -100.00bn | -100.00bn | 265.26m | 406.00 | -- | -- | -- | -- | -- | -- | -- | 0.9818 | -- | -- | -- | -- | -- | -7.91 | -- | -10.85 | -- | 32.86 | -- | -23.15 | 1.67 | -- | 0.787 | -- | 0.4725 | -4.24 | -575.39 | -- | -12.85 | -- |
| Abeona Therapeutics Inc | 400.00k | 82.35m | 271.50m | 136.00 | 4.53 | 1.53 | 3.21 | 678.75 | 1.11 | 1.11 | 0.0073 | 3.27 | 0.0023 | -- | 0.2478 | 2,941.18 | 46.83 | -62.23 | 52.94 | -78.23 | -122.00 | -- | 20,587.50 | -1,824.21 | 9.53 | -- | 0.1034 | -- | -100.00 | -- | -17.62 | -- | -17.78 | -- |
| Evolus Inc | 285.82m | -58.56m | 278.73m | 329.00 | -- | -- | -- | 0.9752 | -0.9125 | -0.9125 | 4.46 | -0.4441 | 1.27 | 4.09 | 6.01 | 860,912.60 | -26.11 | -37.04 | -36.48 | -57.14 | 65.83 | 65.19 | -20.49 | -51.26 | 1.53 | -2.13 | 1.25 | -- | 31.76 | 50.12 | 18.26 | -- | 1.10 | -- |
Data as of Feb 13 2026. Currency figures normalised to Journey Medical Corp's reporting currency: US Dollar USD
25.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 30 Sep 2025 | 1.85m | 6.80% |
| Wasatch Advisors LPas of 31 Dec 2025 | 1.32m | 4.83% |
| Opaleye Management, Inc.as of 30 Sep 2025 | 971.06k | 3.56% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 664.38k | 2.44% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 655.76k | 2.41% |
| Summit Financial LLCas of 31 Dec 2025 | 390.42k | 1.43% |
| Essex Investment Management Co. LLCas of 31 Dec 2025 | 345.98k | 1.27% |
| Geode Capital Management LLCas of 31 Dec 2025 | 313.97k | 1.15% |
| UBS Securities LLCas of 31 Dec 2025 | 290.23k | 1.07% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 244.00k | 0.90% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
